FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2401604009> ?p ?o ?g. }

• W2401604009 endingPage "634" @default.
• W2401604009 startingPage "627" @default.
• W2401604009 abstract "Photoangiolytic laser treatment of recurrent respiratory papillomatosis (RRP) is effective, but does not reliably prevent recurrence. Therefore, sublesional injections of the antiangiogenic agent bevacizumab (Avastin) were given to assess the adjunctive effect on disease recurrence. Since bevacizumab is a new therapeutic modality for RRP, there were also primary safety objectives to determine whether there was a pegative impact on the voice and whether there were local or systemic complications.A prospective open-label investigation was conducted in 20 adult patients with bilateral vocal fold RRP. The patients underwent planned 532-nm pulsed KTP laser photoangiolysis of bilateral glottal disease 4 times with an approximately 6-week interval between procedures. At each planned laser procedure, the vocal fold that on initial presentation had a greater volume of disease also underwent 4 serial sublesional bevacizumab injections (7.5 to 12.5 mg in 0.3 to 0.5 mL). A sham injection with saline solution was administered to the other vocal fold as a control. Disease resolution was compared between subjects' vocal folds, and objective measures of vocal function (acoustic, aerodynamic), as well as patients' self-assessments of vocal function (Voice-Related Quality of Life survey), were obtained.All 20 patients completed the study, and there were no local or systemic complications. After 4 injections, 3 of the 20 patients had no discernible disease in either vocal fold. Of the remaining 17 subjects, 16 had less disease in the bevacizumab-treated vocal fold despite starting with more disease. Only 1 of the 17 had more disease in the bevacizumab-treated vocal fold after 4 injections. Moreover, 7 of the 20 patients (35%) did not require a laser procedure in the vocal fold that had received 4 bevacizumab injections, as compared with 3 of the 20 vocal folds (15%) that were treated with laser alone. All of the vocal function measures displayed statistically significant posttreatment improvements, except for average fundamental frequency in the 3 female patients, in whom it fell below the normal range.This prospective investigation provided evidence that bevacizumab injections enhanced KTP laser treatment of glottal papillomatosis without systemic or local complications. Coupling the antiangiogenesis agent bevacizumab with KTP laser photoangiolysis is conceptually synergistic and scientifically promising since the mechanisms of action are complementary." @default.
• W2401604009 created "2016-06-24" @default.
• W2401604009 creator A5007529506 @default.
• W2401604009 creator A5023488652 @default.
• W2401604009 creator A5026013446 @default.
• W2401604009 creator A5032364494 @default.
• W2401604009 creator A5039558708 @default.
• W2401604009 creator A5069181244 @default.
• W2401604009 creator A5078548743 @default.
• W2401604009 creator A5088515918 @default.
• W2401604009 creator A5090214917 @default.
• W2401604009 date "2011-10-01" @default.
• W2401604009 modified "2023-10-18" @default.
• W2401604009 title "Local Injection of Bevacizumab (Avastin) and Angiolytic KTP Laser Treatment of Recurrent Respiratory Papillomatosis of the Vocal Folds: A Prospective Study" @default.
• W2401604009 cites W1978139448 @default.
• W2401604009 cites W2009297256 @default.
• W2401604009 cites W2011108910 @default.
• W2401604009 cites W2011973646 @default.
• W2401604009 cites W2020667364 @default.
• W2401604009 cites W2029119558 @default.
• W2401604009 cites W2029519409 @default.
• W2401604009 cites W2030288291 @default.
• W2401604009 cites W2032482869 @default.
• W2401604009 cites W2036370866 @default.
• W2401604009 cites W2039446733 @default.
• W2401604009 cites W2054401939 @default.
• W2401604009 cites W2068780497 @default.
• W2401604009 cites W2072862527 @default.
• W2401604009 cites W2090424277 @default.
• W2401604009 cites W2099998343 @default.
• W2401604009 cites W2129349255 @default.
• W2401604009 cites W2150766933 @default.
• W2401604009 cites W2166348640 @default.
• W2401604009 cites W2314853688 @default.
• W2401604009 cites W2324677651 @default.
• W2401604009 cites W2411386213 @default.
• W2401604009 cites W2462872364 @default.
• W2401604009 cites W4211002736 @default.
• W2401604009 cites W4248968607 @default.
• W2401604009 cites W4249132801 @default.
• W2401604009 doi "https://doi.org/10.1177/000348941112001001" @default.
• W2401604009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22097147" @default.
• W2401604009 hasPublicationYear "2011" @default.
• W2401604009 type Work @default.
• W2401604009 sameAs 2401604009 @default.
• W2401604009 citedByCount "91" @default.
• W2401604009 countsByYear W24016040092012 @default.
• W2401604009 countsByYear W24016040092013 @default.
• W2401604009 countsByYear W24016040092014 @default.
• W2401604009 countsByYear W24016040092015 @default.
• W2401604009 countsByYear W24016040092016 @default.
• W2401604009 countsByYear W24016040092017 @default.
• W2401604009 countsByYear W24016040092018 @default.
• W2401604009 countsByYear W24016040092019 @default.
• W2401604009 countsByYear W24016040092020 @default.
• W2401604009 countsByYear W24016040092021 @default.
• W2401604009 countsByYear W24016040092022 @default.
• W2401604009 countsByYear W24016040092023 @default.
• W2401604009 crossrefType "journal-article" @default.
• W2401604009 hasAuthorship W2401604009A5007529506 @default.
• W2401604009 hasAuthorship W2401604009A5023488652 @default.
• W2401604009 hasAuthorship W2401604009A5026013446 @default.
• W2401604009 hasAuthorship W2401604009A5032364494 @default.
• W2401604009 hasAuthorship W2401604009A5039558708 @default.
• W2401604009 hasAuthorship W2401604009A5069181244 @default.
• W2401604009 hasAuthorship W2401604009A5078548743 @default.
• W2401604009 hasAuthorship W2401604009A5088515918 @default.
• W2401604009 hasAuthorship W2401604009A5090214917 @default.
• W2401604009 hasConcept C141071460 @default.
• W2401604009 hasConcept C188816634 @default.
• W2401604009 hasConcept C2776694085 @default.
• W2401604009 hasConcept C2777802072 @default.
• W2401604009 hasConcept C2780336059 @default.
• W2401604009 hasConcept C2780474809 @default.
• W2401604009 hasConcept C2910019179 @default.
• W2401604009 hasConcept C71924100 @default.
• W2401604009 hasConceptScore W2401604009C141071460 @default.
• W2401604009 hasConceptScore W2401604009C188816634 @default.
• W2401604009 hasConceptScore W2401604009C2776694085 @default.
• W2401604009 hasConceptScore W2401604009C2777802072 @default.
• W2401604009 hasConceptScore W2401604009C2780336059 @default.
• W2401604009 hasConceptScore W2401604009C2780474809 @default.
• W2401604009 hasConceptScore W2401604009C2910019179 @default.
• W2401604009 hasConceptScore W2401604009C71924100 @default.
• W2401604009 hasIssue "10" @default.
• W2401604009 hasLocation W24016040091 @default.
• W2401604009 hasLocation W24016040092 @default.
• W2401604009 hasOpenAccess W2401604009 @default.
• W2401604009 hasPrimaryLocation W24016040091 @default.
• W2401604009 hasRelatedWork W2003938723 @default.
• W2401604009 hasRelatedWork W2047967234 @default.
• W2401604009 hasRelatedWork W2118496982 @default.
• W2401604009 hasRelatedWork W2439875401 @default.
• W2401604009 hasRelatedWork W2914664778 @default.
• W2401604009 hasRelatedWork W2979816327 @default.
• W2401604009 hasRelatedWork W3194974361 @default.
• W2401604009 hasRelatedWork W4308452871 @default.
• W2401604009 hasRelatedWork W4380186280 @default.

• next